As I posted earlier Trump tried this is 2020 and at least then was directed at the "Top 50 medications that account for the highest spending under Medicare’s Part B benefit, which covers drugs administered in doctors' offices, such as cancer infusions"
With ChatGPT help i find that "Given that Sofdra is a topical gel prescribed for home use, it is covered under Medicare Part D, not Part B. Therefore, it is unlikely to be directly affected by the new pricing policy, which targets Part B drugs"
It's starting to sound much less likely we will be affected. We aren't in the Top50 and we aren't in the Part B benefit. This is assuming that the 2025 order is the same as the 2020 order which i am pretty certain will be the case. This is a re-run of the 2020 attempt.
However the price will not recover until it is spelled out in the order. if you are brave, there some quick $$ to be made. I am sure Trump will not leave pharma in the dark for too long. We will know by tomorrow if we are affected or not.
BOT Price at posting:
38.3¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)